title: XP-828l in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study.
abstract: BACKGROUND
  XP-828L, a protein extract obtained from sweet whey, has demonstrated potential benefit for the treatment of mild to moderate psoriasis in an open-label study.
  
  
  OBJECTIVE
  To study in a randomized, double-blind, placebo-controlled study the safety and efficacy of XP-828L in the treatment of mild to moderate psoriasis.
  
  
  METHODS
  XP-828L 5 g/d (group A, n = 42) or placebo (group B, n = 42) was given orally for 56 days followed by XP-828L 5 g/d in group A and by XP-828L 10 g/d in group B for an additional 56 days.
  
  
  RESULTS
  Patients receiving XP-828L 5 g/d for 56 days had an improved Physician's Global Assessment (PGA) score compared with patients under placebo (p < .05). Considering the data of group A only, the PGA score improved from day 1 to day 56 (p < .01); the Psoriasis Area and Severity Index score improved as well, but to a lesser extent (p < .05).
  
  
  CONCLUSIONS
  Oral administration of 5 g/d XP-828L compared with a placebo significantly improved the PGA score of patients with mild to moderate psoriasis.
authors.affiliation: Centre de Recherche Dermatologique du Québec Métropolitain Québec, Canada.
authors.forename: Yves
authors.initials: Y
authors.lastname: Poulin
authors.forename: Robert
authors.initials: R
authors.lastname: Bissonnette
authors.forename: Christina
authors.initials: C
authors.lastname: Juneau
authors.forename: Kim
authors.initials: K
authors.lastname: Cantin
authors.forename: Rejean
authors.initials: R
authors.lastname: Drouin
authors.forename: Patrice E
authors.initials: PE
authors.lastname: Poubelle
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D016009:Chi-Square Distribution; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008894:Milk Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D008894:Milk Proteins; D010919:Placebos; C518519:XP-828l